|
Driven by advances in molecular probe design and biomarker detection
methodologies, new imaging agents that can improve visualization of
pathologies and cellular processes are changing the practice of
diagnostic medicine. The ability of this new generation of contrast
agents to detect metabolic changes at the molecular level has
significant potential for improving visualization and quality of care.
Targetable and activatable imaging agents are gaining interest for a
wide range of diagnostic applications that include cardiology, neurology
and soft tissue tumor detection. The number of healthcare conditions
that can be effectively imaged noninvasively
is expanding as a result of these innovative detection
technologies. Targeted and
activatable imaging agents offer a unique capability to generate
unambiguous images by exploiting specific molecular targets, pathways or
cellular processes. This new wave of imaging agents signals a paradigm
shift in which the reagents take on new importance alongside system
hardware in revenue projections and product line ROI.
Publication Date: July 2007 |